Opdivo combination regimens received FDA approval for previously untreated, Stage III or IV cHL and EC approval in R/R cHL after one prior line of therapy March 24, 2026
Enrollment progress update provided on Ph 3 TERZO study of COPIKTRA (duvelisib) in adults with R/R nodal TFHL December 30, 2025
FDA Grants Priority Review to supplemental BLA for Opdivo® + Chemo Combo for Classical Hodgkin Lymphoma December 15, 2025
EC Approves ADCETRIS® (brentuximab vedotin) for the Treatment of 1L Patients with Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD June 10, 2025
First Patient enrolled in Ph 2 Trial of Ethanol-Free Carmustine in High-Dose Chemotherapy Prior to Transplant in Patients with HL or NHL April 22, 2025
FDA granted RMAT designation to acimtamig and AlloNK (AB101) for the treatment of R/R HL December 10, 2024
EC Approves ADCETRIS + AVD combo for Adult Patients with 1L CD30+ Stage III Hodgkin Lymphoma October 25, 2023
Ph 3 Trial of ADCETRIS (brentuximab vedotin) with Modified Chemo Regimen Shows Non-Inferiority with 3-Year PFS of 94.9% vs Less Tolerable SoC in cHL June 28, 2023
6-Year OS Results Added to US Prescribing Information for ADCETRIS® (brentuximab vedotin) as 1L Treatment for Advanced Hodgkin Lymphoma June 21, 2023
